Vera Kadlecek
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
Journal: Nature communications
Published: April 14, 2026
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 01, 2025
Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: October 21, 2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 09, 2024
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
Journal: The Lancet. Infectious diseases
Published: September 20, 2023
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults.
Journal: The Lancet. Infectious diseases
Published: January 16, 2023
Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.
Journal: Travel medicine and infectious disease
Published: December 19, 2019
Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
Journal: The Pediatric infectious disease journal
Published: June 19, 2018
Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.
Journal: Travel medicine and infectious disease
Published: November 02, 2017
Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.
Journal: The Pediatric infectious disease journal
Published: April 26, 2017
Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
Journal: The Pediatric infectious disease journal
Published: April 22, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026